A dual-receptor targeting delivery system based on acid-cleavage hydrazone bond was developed in the study. The characters of CMCS-hyd-CUR-EGFR-mAb were identified. The in vitro release studies revealed that this drug...A dual-receptor targeting delivery system based on acid-cleavage hydrazone bond was developed in the study. The characters of CMCS-hyd-CUR-EGFR-mAb were identified. The in vitro release studies revealed that this drug delivery system was acid-sensitive, and the self-assembled nanoparticles which were spherical. The in vitro results indicated that the dual-receptor targeting nanoparticles could be faster internalized into the Cal-27 cells via receptor-mediated endocytosis, which exhibited better antitumor activity than the one-receptor nanoparticles. The experimental results clearly reveal that CMCS-hyd-CUR-EGFR mAb provides a novel way for drug delivery in oral cancer treatment.展开更多
This work aimed to develop an intelligent multi-target tracking hyaluronic acid-RGDchlorambucil-quantum dots（HA-RGD-CLB-QDs） drug delivery system. After deacetylated, hyaluronic acid was reacted with anticancer drug...This work aimed to develop an intelligent multi-target tracking hyaluronic acid-RGDchlorambucil-quantum dots（HA-RGD-CLB-QDs） drug delivery system. After deacetylated, hyaluronic acid was reacted with anticancer drug chlorambucil, RGD, and quantum dots to obtain the HA-RGD-CLB-QDs drug delivery system. The characterization by FT-IR, ~1 H NMR, TEM, XPS, DLS, and UV-vis absorption and fluorescence spectra show that the system is successfully constructed with an average particle size of about 70 nm. The results of the drug release profile show that that the system has a p H and enzyme sensitive controlled release behaviour. Moreover, cellular uptake and toxicity results show that the system has an ideal dual receptormediated endocytosis pathway that significantly enhances the efficacy of CLB tumor therapy and has a lower toxicity to normal cells.The system shows the potential application as a carrier for cancer therapy.展开更多
<strong>Aim: </strong>In this review paper we propose a method to make an early diagnosis of the Alzheimer’s Disease (AD), the most common form of neurodegenerative dementia. <strong>Background:<...<strong>Aim: </strong>In this review paper we propose a method to make an early diagnosis of the Alzheimer’s Disease (AD), the most common form of neurodegenerative dementia. <strong>Background:</strong> Glymphatic System (GS) is the main means of eliminating waste substances in the central nervous system (CNS);if it does not work properly, waste substances accumulate in CNS until to cause AD. Basal Forebrain is the most important component of a much broader system of cholinergic cells distributed throughout the Central Nervous System (CNS). This structure regulates attention, learning and memory and its destruction is considered responsible for the cognitive AD alterations. The characteristics of AD patients, that interest us most, are the lack of Acetylcholine, and the Orexin excess;we think that the hypothalamus produces more Orexin to stimulate cholinergic cells, indispensable for a correct CNS functioning. We want to identify these patients by detecting the Orexin excess. Early Diagnosis Model. Of course we could take a cerebrospinal fluid sample and dose Orexin but this method is risky and painful for the patient’s health, therefore unsuitable for large numbers of patients. We propose a fairly simple method for the early diagnosis of AD: if we temporarily eliminate the Orexin excess, with Dual Orexin Receptor Antagonist (DORA), i.e. Suvorexant, we can intercept the Orexin increase and demonstrate the decrease in Acetylcholine with a Functional Magnetic Resonance or a Polysomnography, many years before the AD symptoms occur.展开更多
目的:探讨胰高血糖素样肽-1(GLP-1)蛋白对帕金森病氧化应激损伤的保护作用及机制。方法:36只8周龄C57BL/6雄性小鼠随机平分为三组(模型组、利拉鲁肽组与GLP-1组)。所有小鼠都给予建立帕金森病模型,模型组在建模过程中给予0.1 ml 0.9%氯...目的:探讨胰高血糖素样肽-1(GLP-1)蛋白对帕金森病氧化应激损伤的保护作用及机制。方法:36只8周龄C57BL/6雄性小鼠随机平分为三组(模型组、利拉鲁肽组与GLP-1组)。所有小鼠都给予建立帕金森病模型,模型组在建模过程中给予0.1 ml 0.9%氯化钠溶液注射,利拉鲁肽组在给予利拉鲁肽腹腔注射25 nmol/(kg·d),GLP-1组在建给予GLP-1/GIP双受体激动剂(DA3-CH)腹腔注射25 nmol/(kg·d),连续治疗7 d。结果:三组建模第7天的转棒停留时间、牵拉肌张力评分都低于建模第1天(均P<0.05),利拉鲁肽组与GLP-1组高于模型组(P<0.05),GLP-1组高于利拉鲁肽组(均P<0.05)。利拉鲁肽组与GLP-1组建模第7天的血清Chi3l1含量、脑组织IBA-1和胶质纤维酸性蛋白(GFAP)相对表达水平低于模型组(均P<0.05),GLP-1组低于利拉鲁肽组(P<0.05)。结论:GLP-1蛋白在帕金森病小鼠的应用能缓解氧化应激损伤,抑制血清Chi3l1与脑组织IBA-1、GFAP蛋白的表达,从而发挥神经保护作用。展开更多
基金Funded by the National Natural Science Foundation of China(Nos.81771080 and 8131147)the Opening Project of Hubei Key Laboratory of Purification and Application of Plant Anti-cancer Active Ingredients(No.HLPAI 2014006)the Health Commission of Hubei Province Scientific Research Project(No.WJ2019H275)
文摘A dual-receptor targeting delivery system based on acid-cleavage hydrazone bond was developed in the study. The characters of CMCS-hyd-CUR-EGFR-mAb were identified. The in vitro release studies revealed that this drug delivery system was acid-sensitive, and the self-assembled nanoparticles which were spherical. The in vitro results indicated that the dual-receptor targeting nanoparticles could be faster internalized into the Cal-27 cells via receptor-mediated endocytosis, which exhibited better antitumor activity than the one-receptor nanoparticles. The experimental results clearly reveal that CMCS-hyd-CUR-EGFR mAb provides a novel way for drug delivery in oral cancer treatment.
基金Funded by the National Natural Science Foundation of China(Nos.51473130 and 51572206)the Wuhan Huanghe Excellence Plan and Entrepreneurship Training Program of Wuhan University and Technology(Nos.20171049720018,20171049720019 and 20171049720009)
文摘This work aimed to develop an intelligent multi-target tracking hyaluronic acid-RGDchlorambucil-quantum dots（HA-RGD-CLB-QDs） drug delivery system. After deacetylated, hyaluronic acid was reacted with anticancer drug chlorambucil, RGD, and quantum dots to obtain the HA-RGD-CLB-QDs drug delivery system. The characterization by FT-IR, ~1 H NMR, TEM, XPS, DLS, and UV-vis absorption and fluorescence spectra show that the system is successfully constructed with an average particle size of about 70 nm. The results of the drug release profile show that that the system has a p H and enzyme sensitive controlled release behaviour. Moreover, cellular uptake and toxicity results show that the system has an ideal dual receptormediated endocytosis pathway that significantly enhances the efficacy of CLB tumor therapy and has a lower toxicity to normal cells.The system shows the potential application as a carrier for cancer therapy.
文摘<strong>Aim: </strong>In this review paper we propose a method to make an early diagnosis of the Alzheimer’s Disease (AD), the most common form of neurodegenerative dementia. <strong>Background:</strong> Glymphatic System (GS) is the main means of eliminating waste substances in the central nervous system (CNS);if it does not work properly, waste substances accumulate in CNS until to cause AD. Basal Forebrain is the most important component of a much broader system of cholinergic cells distributed throughout the Central Nervous System (CNS). This structure regulates attention, learning and memory and its destruction is considered responsible for the cognitive AD alterations. The characteristics of AD patients, that interest us most, are the lack of Acetylcholine, and the Orexin excess;we think that the hypothalamus produces more Orexin to stimulate cholinergic cells, indispensable for a correct CNS functioning. We want to identify these patients by detecting the Orexin excess. Early Diagnosis Model. Of course we could take a cerebrospinal fluid sample and dose Orexin but this method is risky and painful for the patient’s health, therefore unsuitable for large numbers of patients. We propose a fairly simple method for the early diagnosis of AD: if we temporarily eliminate the Orexin excess, with Dual Orexin Receptor Antagonist (DORA), i.e. Suvorexant, we can intercept the Orexin increase and demonstrate the decrease in Acetylcholine with a Functional Magnetic Resonance or a Polysomnography, many years before the AD symptoms occur.
